摘要
目的探讨核因子κB p65(NF-κB p65)表达与卵巢癌化疗耐药的关系。方法收集中国医科大学附属盛京医院2006—2012年符合纳入条件并完善随访的原发性上皮性卵巢癌患者176例,敏感组101例,耐药组75例。采用免疫组化法测定两组中NF-κB p65的表达情况,探讨其表达与卵巢癌化疗耐药的关系。结果 NF-κB p65在敏感组的表达程度明显低于耐药组(P<0.05)。卵巢癌的病理分期、淋巴结转移和NF-κB p65的表达均为耐药性相关的独立危险因素(P均<0.05)。病理分期、NF-κB p65的表达均为卵巢癌预后独立危险因素(P均<0.05)。结论 NF-κB p65的高度表达是卵巢癌患者化疗耐药的高危因素。
Objective To explore the correlation of the expression between NF-κB p65 and chemoresistance in ovarian epithelial cancers. Methods Totaly176 patients with primary epithelial ovarian cancer admitted to Shengjing Hospital of China Medical University between 2006 and 2012, who met the inclusion criteria, and were successfully followed up, were included in the study, and they were divided into two groups: sensitive group (n=101) and resistant group (n= 75). Expression of NF-κB p65 in the ovarian cancer tissues was determined using immunohistochemistry and its correlation with chemoresistance was studied. Results The expression of NF- κB p65 in the sensitive group was significantly lower than that in resistant group(P 〈0.05). Surgical stage of ovarian cancer,lymphatic metastasis and expression of NF-κB p65 were independent risk factors associated with drug resistance (all P〈0.05). Surgical stage and expression of NF- κB p65 were independent prognostic risk factors of ovarian cancer(all P〈0.05). Conclusions High expression of NF- κB is high risk factor for chemoresistance in ovarian cancer patients.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2015年第10期968-971,共4页
Chinese Journal of Practical Gynecology and Obstetrics
基金
国家自然科学基金(81372486)
辽宁省博士启动基金(20071047)
辽宁省教育厅高等学校科研项目计划(2009A724)
辽宁省科学技术(2010225032)